Lead author

Neuraptive Therapeutics, Inc. Announces Positive 24-Week Data for NTX-001 in the Phase 2 NEUROFUSE Study, Reinforcing Previously Announced Proof of Concept 12-Week Data

Retrieved on: 
Thursday, February 22, 2024

At the 24-week mark, NTX-001 continues to demonstrate an encouraging safety profile, with lower treatment-emergent adverse event rates than the standard of care.

Key Points: 
  • At the 24-week mark, NTX-001 continues to demonstrate an encouraging safety profile, with lower treatment-emergent adverse event rates than the standard of care.
  • The secondary endpoints, including the Numerical Pain Rating Scale, also showed statistically significant improvements, favoring NTX-001 at the 24-week timepoint.
  • Neuraptive Therapeutics, Inc. is dedicated to the innovation and development of medical products and therapeutics to repair and regenerate peripheral nerves.
  • Neuraptive Therapeutics, Inc. disclaims any obligation to update the information contained in these forward-looking statements.

Renowned Gartner Analyst Ankush Jain joins DQLabs

Retrieved on: 
Tuesday, October 10, 2023

PASADENA Calif., Oct. 10, 2023 /PRNewswire/ -- DQLabs , the Modern Data Quality company, today announced that Ankush Jain , a highly respected former Gartner Analyst, Augmented Data Quality, Data Observability and Data Management at Gartner, has joined DQLabs as Head of Marketing and Product Strategy.

Key Points: 
  • PASADENA Calif., Oct. 10, 2023 /PRNewswire/ -- DQLabs , the Modern Data Quality company, today announced that Ankush Jain , a highly respected former Gartner Analyst, Augmented Data Quality, Data Observability and Data Management at Gartner, has joined DQLabs as Head of Marketing and Product Strategy.
  • Ankush Jain, a former Gartner Analyst, joins forces with Modern Data Quality company DQLabs.
  • Ankush's accomplished career at Gartner included serving as the Lead Author for the Data Quality Magic Quadrant and leading the evolution of the market towards Augmented Data Quality.
  • With DQLabs' continued focus towards providing a Modern data Quality platform that converges Augmented Data Quality & Data Observability powered by Semantic Layer and GenAI capabilities, this addition comes timely and quite valuable as we continue to scale," said Raj Joseph, Founder & CEO of DQLabs.

Helsinn announces publication of data evaluating impact of AKYNZEO® (fosnetupitant/palonosetron) on treatment outcomes and healthcare costs

Retrieved on: 
Monday, June 12, 2023

The dataset provides insight to nearly 80% of the US healthcare system, with patient-level data from all provider types.

Key Points: 
  • The dataset provides insight to nearly 80% of the US healthcare system, with patient-level data from all provider types.
  • Referring to the details of the publication below, these real-world data showed that healthcare resource utilization, such as CINV-related visits were significantly lower after AKYNZEO® compared to fosaprepitant/palonosetron (APPA).
  • CINV-related healthcare costs were also statistically and/or numerically lower for patients receiving AKYZNEO® compared to APPA.
  • There remains a gap between expected and actual patient outcomes as clinicians translate trial data and clinical guidelines into practice.

Drown Prevention Summit Hosted by Paralympian Jamal Hill of Aquatics Today to Focus on Keeping Communities Safe Around Water

Retrieved on: 
Tuesday, June 14, 2022

The virtual summit will be hosted by Aquatics Today beginning at 10:30 a.m. PST.

Key Points: 
  • The virtual summit will be hosted by Aquatics Today beginning at 10:30 a.m. PST.
  • This free event will focus on everything you need to know about drowning prevention, from global expert insights to best practices and new data.
  • Jamal Hill, Paralympic Medalist and Managing Director of Aquatics Today will host the Drown Prevention Summit.
  • Aquatics Today has one goal in mind: to help the recreational aquatics community build enjoyable swimming programs and effective water safety initiatives.

Merus Presents Clinical Data on Zenocutuzumab (Zeno) in NRG1-fusion (NRG1+) Cancer at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting (Oral Abstract)

Retrieved on: 
Sunday, June 5, 2022

We believe Zeno has the potential to be both first in class and best in class as a tumor agnostic treatment for patients with NRG1+ cancer.

Key Points: 
  • We believe Zeno has the potential to be both first in class and best in class as a tumor agnostic treatment for patients with NRG1+ cancer.
  • There are currently no approved therapies targeting NRG1 fusion-positive cancer and Zeno offers an important, potential new standard of care.
  • The eNRGy trial consists of three cohorts: NRG1+ pancreatic cancer; NRG1+ non-small cell lung cancer; and NRG1+ cancer.
  • Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics.

Largest Study to Date on COVID19 Pregnancy Outcomes Published in American Journal of Obstetrics and Gynecology

Retrieved on: 
Friday, January 14, 2022

MESA, Ariz., Jan. 14, 2022 PRNewswire/ -- Newly published today in the American Journal of Obstetrics and Gynecology is the largest study performed thus far on the effect of the COVID19 virus in pregnancy.

Key Points: 
  • MESA, Ariz., Jan. 14, 2022 PRNewswire/ -- Newly published today in the American Journal of Obstetrics and Gynecology is the largest study performed thus far on the effect of the COVID19 virus in pregnancy.
  • "In the largest study to date, a strong connection between COVID19 infection in pregnancy and preterm birth is seen."
  • Marchand holds dual certifications from the American Board of Obstetrics and Gynecology in both general OBGYN and Minimally Invasive Gynecologic Surgery.
  • About The American Journal of Obstetrics and Gynecology:AJOG Global Reports is one of two companion titles to the highly-respected American Journal of Obstetrics and Gynecology.

MARQUE Luxury Opens New Showroom Location in Charlotte, North Carolina

Retrieved on: 
Tuesday, November 9, 2021

CHARLOTTE, N.C., Nov. 9, 2021 /PRNewswire/ --MARQUE Luxury, the Leading Authority in Wholesale Pre-Owned Designer Goods, Announced the Opening of its Charlotte North Carolina Located at 112 S. Tryon St. Charlotte, NC.

Key Points: 
  • CHARLOTTE, N.C., Nov. 9, 2021 /PRNewswire/ --MARQUE Luxury, the Leading Authority in Wholesale Pre-Owned Designer Goods, Announced the Opening of its Charlotte North Carolina Located at 112 S. Tryon St. Charlotte, NC.
  • MARQUE'S Charlotte's showroom is the first location in North Carolina and the fourth East Coast location.
  • MARQUE's showrooms carry authentic luxury brands including Louis Vuitton, Gucci, Chanel, Hermes, and more.
  • Clients have access to their showroom for accessibility to view products in hand, in a safe and hands-on experience.

Katie Ledecky, Olympic Champion Swimmer, Signs With Leading Authorities for Exclusive Speaking Representation

Retrieved on: 
Thursday, October 28, 2021

WASHINGTON, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Leading Authorities is pleased to announce its exclusive representation of 10-time Olympic medalist and 15-time World Champion medalist swimmer Katie Ledecky for speaking engagements.

Key Points: 
  • WASHINGTON, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Leading Authorities is pleased to announce its exclusive representation of 10-time Olympic medalist and 15-time World Champion medalist swimmer Katie Ledecky for speaking engagements.
  • "This is an amazing opportunity to hear directly from one of the most successful athletes of all time," said Matt Jones, president and CEO of Leading Authorities.
  • "Katie Ledecky is the ultimate winner and the insights she shares on peak performance and achieving goals are highly sought after by our clients."
  • And our full-service event production company LAI Live designs, produces, and manages events of all formats to create memorable and engaging experiences.

Wysa, the Leading AI-Powered Mental Health Platform Welcomes New Senior Executive Members

Retrieved on: 
Wednesday, October 13, 2021

Zereana will lead the roll out and management of Wysa's US-based therapy network in support of Wysa's AI + expert human model.

Key Points: 
  • Zereana will lead the roll out and management of Wysa's US-based therapy network in support of Wysa's AI + expert human model.
  • "As a society, we must reimagine the way we think about mental health care.
  • Wysa is a global leader in AI-driven mental health support, available both to individuals and through employer benefits programs.
  • For employers, Wysa offers a workplace solution that caters to the full spectrum of mental health needs.